Core Insights - OSE Immunotherapeutics has announced a strategic amendment to its partnership with AbbVie regarding the development of ABBV-230, a monoclonal antibody aimed at addressing chronic and severe inflammation [1][2] - The revised agreement allows OSE Immunotherapeutics to regain control over the early-stage development of ABBV-230, while AbbVie retains rights for future development and commercialization after Phase 1 [2][5] Summary by Sections Partnership Structure - OSE Immunotherapeutics will lead the preclinical and Phase 1 development of ABBV-230, utilizing its expertise in immunology [8] - AbbVie remains the exclusive licensee and will control development and commercialization post-Phase 1 [8] Financial Terms - Existing commercialization rights, including royalties on global net sales and sales-based milestone payments, remain unchanged [8] - OSE Immunotherapeutics will not receive the previously anticipated milestone payment for initiating the Phase 1 study but can earn milestone payments in later development stages if AbbVie advances the candidate [8] Product Development - ABBV-230 targets ChemR23, a dual-function receptor that plays a significant role in inflammation regulation and is being explored as a first-in-class therapy for inflammation resolution [4][5]